Harrow Health (HROW) Misses Q4 EPS by 23c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Harrow Health Announces Fourth Quarter and Year-End 2021 Financial Results
March 10, 2022 4:01 PM ESTSixth Consecutive Quarter of Record RevenuesÂ
Highlights for Fourth Quarter 2021:
Record revenues of $20.2 million, a 38% increase compared with $14.6 million for the prioryear quarter; Gross profit was a record $15.1 million, a 42% increase compared with $10.7 million for the prioryear quarter; Gross margin increased to 75% compared with 73% in the prior-year quarter; FDA acceptance of AMP-100 NDA and assignment of PDUFA target date of October 16, 2022; Commissions from DEXYCU® sales increased to $1.0 million on record unit volumes; and Cash and cash equivalents was $42.2 million at December 31,... More